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AbstrACt
Introduction Recent studies suggest that endoplasmic 
reticulum stress may play a critical role in the pathogenesis 
of amyotrophic lateral sclerosis (ALS) through an altered 
regulation of the proteostasis, the cellular pathway-
balancing protein synthesis and degradation. A key 
mechanism is thought to be the dephosphorylation 
of eIF2α, a factor involved in the initiation of protein 
translation. Guanabenz is an alpha-2-adrenergic receptor 
agonist safely used in past to treat mild hypertension and 
is now an orphan drug. A pharmacological action recently 
discovered is its ability to modulate the synthesis of 
proteins by the activation of translational factors preventing 
misfolded protein accumulation and endoplasmic reticulum 
overload. Guanabenz proved to rescue motoneurons from 
misfolding protein stress both in in vitro and in vivo ALS 
models, making it a potential disease-modifying drug 
in patients. It is conceivable investigating whether its 
neuroprotective effects based on the inhibition of eIF2α 
dephosphorylation can change the progression of ALS.
Methods and analyses Protocolised Management 
In Sepsis is a multicentre, randomised, double-blind, 
placebo-controlled phase II clinical trial with futility design. 
We will investigate clinical outcomes, safety, tolerability 
and biomarkers of neurodegeneration in patients with ALS 
treated with guanabenz or riluzole alone for 6 months. 
The primary aim is to test if guanabenz can reduce the 
proportion of patients progressed to a higher stage of 
disease at 6 months compared with their baseline stage as 
measured by the ALS Milano-Torino Staging (ALS-MITOS) 
system and to the placebo group. Secondary aims are 
safety, tolerability and change in at least one biomarker of 
neurodegeneration in the guanabenz arm compared with 
the placebo group. Findings will provide reliable data on 
the likelihood that guanabenz can slow the course of ALS 
in a phase III trial.
Ethics and dissemination The study protocol was 
approved by the Ethics Committee of IRCCS ‘Carlo Besta 
Foundation’ of Milan (Eudract no. 2014-005367-32 Pre-
results) based on the Helsinki declaration.
IntroduCtIon
Background and rationale
Recent evidence highlighted the crucial 
role that accumulation of misfolded protein 
aggregates in neurons and glial cells and 
failure of clearance mechanisms have in the 
strengths and limitations of this study
 ► Amyotrophic lateral sclerosis (ALS) is a rare disease 
and randomised controlled trial (RCT) striving to 
obtain reliable data on the efficacy of candidate 
neuroprotective molecules should be performed 
with a multicentre design. Our consortium, 
including 25 ALS centres in Italy, satisfies the 
criteria of complementarily and synergy needed 
for a multicentre RCT. The coordinating centre is 
experienced in leading RCTs and the participating 
centres have a long-standing collaboration in the 
field of ALS, both in the clinical management of 
patients and clinical research. This will guarantee a 
standardised approach in all the patients.
 ► The study drug, guanabenz, has a mechanism 
of action close to pathogenic changes currently 
considered central to the pathogenesis of ALS, and 
preclinical studies are most promising.
 ► The futility design is an original and innovative 
methodological approach to neurodegenerative 
disease clinical trials. It allows optimising time and 
resources for a larger III phase study, but the a priori 
cut-off may be challenging.
 ► The primary outcome is a change in patients’ 
function. It has been chosen to overcome the 
internal validity limitations of the  ALS Functional 
Rating Score-Revised (ALSFRS-R) and to provide 
clinically meaningful results reflecting a concrete, 
though potential, advantage to patients. However, it 
may not be able to capture mild changes.
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pathogenesis of ALS.1 2 These aggregates have toxic prop-
erties and play a key role in the initiation and progression 
of cell loss.3 Protein components of these accumulations, 
found both in sporadic and familiar ALS, include TDP43, 
FUS/TLS and SOD1.4 The endoplasmic reticulum (ER) 
stress plays a critical role through the activation of the 
unfolded protein response (UPR)5 6 that regulates the 
proteostasis,7–9 namely the cellular balance between 
synthesis and degradation of proteins. The UPR is a 
cellular protective response against protein misfolding 
mediated by the upregulation of specific genes regulated 
by ER stress and the inhibition of protein translation.10 11 
However, long-term ER stress induces the activation of a 
parallel pathway that involves the activating transcription 
factor 4 (ATF4) and C/EBP homologous protein (CHOP) 
and leads to ER overload, with disruption of proteostasis 
and accumulation of misfolded proteins. Central to 
this mechanism is the increase of eukaryotic translation 
initiation factor 2A (eIF2α) phosphorylation. EIF2α is 
a key factor for protein translation initiation12 and for 
the process known as integrated stress response (ISR). 
Altered eIF2α phosphorylation, and therefore protein 
homeostasis, can affect the survival of cells.13 Among the 
different factors mediating this mechanism, the protein 
kinase RNA-like endoplasmic reticulum kinase (PERK) is 
considered a specific target, being one of the kinases that 
phosphorylates eIF2α and coordinates ISR when the accu-
mulation of misfolded proteins triggers the ER stress.14 
Moreover, misfolded protein aggregates can activate a 
‘prion-like’ mechanism of transmission between cells15 16 
mediated by the activity of ribosomal RNA folding17 18 
that recent data suggest to have a role in the progression 
of motor neuron death and therefore of ALS.19
Guanabenz, an alpha-2-adrenergic receptor agonist, 
blocks the dephosphorylation of eIF2α and modulates the 
activity of ribosomal folding underlying aggregate trans-
mission binding to the V-subunit ribosomal RNA (rRNA), 
thus reducing the accumulation of the aggregates and 
their transmission.18 The two effects of guanabenz as an 
alpha-2 agonist and modifier of protein misfolding are 
based on independent mechanisms of action.20 However, 
the pathway through which guanabenz exerts its effect 
of eIF2α dephosphorylation eventually leading to the 
neuroprotection on motor neurons is unknown. It may 
be possible that guanabenz, through imidazoline recep-
tors, activates a lysososmal degradation pathway21 and 
prevents motor neuron death.22
Therefore, it is conceivable to investigate whether its 
neuroprotective effects based on the inhibition of eIF2α 
dephosphorylation and ribosomal modulation can 
change the progression of ALS.
Our phase II RCT will investigate, using a futility 
study design, clinical outcomes, safety, tolerability and 
biomarkers of disease progression in patients with ALS 
treated with guanabenz or riluzole alone for 6 months. 
Our primary aim is to obtain reliable data for a larger 
phase III trial. Guanabenz, formerly used as an antihy-
pertensive agent,23 is an orphan drug (ORPHA178067) 
granted in 2009 by the  European Medicines Agency for 
the treatment of traumatic spinal cord injury.
Preliminary data
Recent works suggested that ER stress-related activation 
of UPR leading to unbalance between protein produc-
tion and degradation and spreading of toxic aggregates 
among motor neurons are two key mechanisms impli-
cated in the pathogenesis of ALS.24 This hypothesis is 
supported both in sporadic and familiar ALS by the 
evidence of abnormal protein folding in motor neurons 
and sequestration of other proteins essential for cell func-
tioning. Affected cells activate protective UPR response, 
which upstream components such as activated ER-resident 
transmembrane proteins (eg, PERK) attenuate global 
protein synthesis by phosphorylating eIF2α and promote 
the translation of transcription factors (eg, ATF4, CHOP) 
which lead to the expression of PPP1R15A, an effector 
of negative feedback loop that terminates UPR signalling 
and dephosphorylates eIF2α allowing protein synthesis 
to resume. UPR failure contributes to many pathological 
conditions that might be corrected by adequate boost of 
this adaptive response. Experimental data suggested that 
misfolding protein, RNA processing defects and toxic 
aggregation and spreading might converge on a common 
pathway leading to motor neuron degeneration.25–28 Most 
recently, salubrinal and guanabenz were found to coun-
teract neuronal toxicity in worm and zebrafish models 
expressing mTDP-43 and mFUS through the reduction 
of ER stress response via UPR.29 These findings strength-
ened the hypothesis that ER stress pathway may be a 
crucial target for therapeutic interventions in ALS. In 
yeast, Drosophila and mouse models, guanabenz showed 
to modulate ribosome folding activity binding the V-sub-
unit rRNA and reducing the prion-like propagation of 
aggregates.30
The therapeutic targets of guanabenz are the inhibi-
tion of stress-induced phosphatase and large subunit 
ribosome impairment. In this way, guanabenz can limit 
stress-induced protein synthesis and proteasome over-
load, allowing a correct cell clearance. This would also 
counteract mechanisms triggering intercell micropi-
nocitosis, the seeds of spreading neurodegeneration. 
Salubrinal prevented muscle waste and prolonged 
survival in SOD1 mouse.26 However, salubrinal does 
not selectivity target ER-stress related phosphatase 
activity and is chemically unstable, making its clin-
ical use unfeasible. Conversely, guanabenz selectively 
inhibits PPP1R15A and tunes translation in stressed 
cells, avoiding intolerable levels of eIF2α phosphory-
lation and dismal low levels of protein synthesis. This 
rescue of proteostasis was found to protect motor 
neuron degeneration in in vitro and in vivo models 
along with the dramatically increased the levels of phos-
phorylated-eIF2α. Proteostatis balance is an important 
mechanism of cell survival. A large number of evidence 
suggests that ER stress-related protein misfolding is 
central to the pathogenesis of ALS. The first line of 
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defence against the accumulation of misfolded proteins 
in the ER consists of phosphorylating the stress-induced 
eIF2α phosphatase.
In the last 3 years, four papers on guanabenz and ALS 
have been published. The first showed that guanabenz 
enhanced the UPR and ameliorates mutant SOD1 ALS 
mice that had a delayed onset and prolonged survival.31 
The second paper demonstrated that guanabenz delays 
the onset of disease symptoms, extends lifespan, improves 
motor performance and attenuates motor neuron loss in 
the SOD1G93A mouse model of ALS, showing to atten-
uate ER stress and mitochondrial stress by prolonged 
eIF2α phosphorylation.32 33 The third paper provided 
further evidence that protein phosphatase inhibition by 
guanabenz and Sephin1 is effective in preventing in vitro 
motor neuron degeneration and in vivo disease progres-
sion. These data further strengthened the hypothesis that 
correcting proteostasis defects leading to accumulation 
of misfolded proteins could benefit a broad range of 
neurodegenerative diseases, including ALS.33
Finally, the fourth experimental paper reported a nega-
tive effect of guanabenz on ALS models.34 The authors 
showed that guanabenz is protective on fibroblasts 
expressing G93A mutant SOD1 when they are exposed 
to tunicamycin-mediated ER stress. However, in contrast 
to the previous reports, the authors reported that 
guanabenz accelerated disease progression in a mixed 
strain of mutant C57BL/6-SJL SOD1 transgenic mice. 
The authors reported altered behaviour in guanabenz-
treated mice of unknown significance, which might have 
been associated with the alternative route of administra-
tion by micropump infusion. The use of different strains, 
the possible different affinity for alpha2 and imidazoline 
receptors, the lack of data on motor neuron pathology 
and survival and on eIF2α phosphorylation make the 
negative results arguable.
Preclinical data have demonstrated that proteostasis 
balance is an important mechanism of cell survival and 
ER-stress related protein misfolding is central to the 
pathogenesis of ALS. The first line of defence against the 
accumulation of misfolded proteins in the ER consists in 
phosphorylating the stress-induced eIF2α phosphatase. In 
vitro data provided strong clues that guanabenz can spare 
the constitutive eIF2α phosphatase and avoid persistent 
eIF2α phosphorylation, which would be lethal to motor 
neurons, while it proved to ameliorate the course of the 
disease in two different ALS mouse models. Therefore, 
the bulk of in vitro and in vivo preclinical evidence in 
favour of a possible positive effect of guanabenz in 
patients with ALS is largely superior to the risk of a wors-
ening of the disease.
MEthods And AnAlysIs
Our phase II RCT will investigate, using a futility 
study design, clinical outcomes, safety, tolerability and 
biomarkers of disease progression in patients with ALS 
treated with guanabenz or riluzole alone for 6 months. 
Our primary aim is to obtain reliable data for a confirma-
tory phase III trial.
objectives
1. To investigate the effect of guanabenz as add-on 
treatment compared with riluzole alone in reducing 
the proportion of patients progressed to higher stages 
of disease over 6 months in sporadic or familial ALS 
patients;
2. To assess safety and tolerability related to alpha2 
receptor agonist activity of guanabenz;
3. To explore serum biomarkers of ALS progression 
(creatinine, albumin) in guanabenz and riluzole 
alone arms at baseline and study end. In patients 
giving consent, the biomarkers will be explored also 
in the cerebrospinal fluid.
Design of the study
This paper is a multicentre, randomised, double-blind, 
placebo-controlled, phase II study with futility design. 
The trial has been designed following the guideline 
on clinical investigation of medicinal products for the 
treatment of ALS provided by the European Medicines 
Agency and adopted by the Agenzia Italiana del Farmaco 
(http://www. agenziafarmaco. gov. it/ it/ content/ 
linea- guida- sui- farmaci- iltrattamento- della- sclerosi- 
laterale- amiotrofica- rilasciata- una- co). The protocol has 
been discussed and revised according to the suggestions 
of the Advisory Board. The Advisory Board of the study 
includes:
 ► Prof Orla Hardiman—Trinity College, University of 
Dublin
 ► Prof Paola Minghetti—University of Milan
 ► Dr Graziella Filippini—IRCCS Foundation ‘Carlo Bes-
ta’ Neurological Institute, Milan
 ► Dr Ettore Beghi—IRCCS ‘Mario Negri’ Institute, Mi-
lan.
The revised protocol has been presented to all the 
participating centres that have given their agreement 
during the Investigator Meeting held on 21 November 
2014, at the Agenize Italiana per la Ricerca sulla Sclerosi 
Laterale Amiotrofica (AriSLA) headquarters, viale Ortles 
21, Milan, Italy.
The study protocol was approved by the Ethics 
Committee of IRCCS Istituto di Ricovero e Cura 
a Carattere Scientifico on 28 October 2015 with 
Eudract Number 2014-005367-32. The authorisation 
of the Agenzia Italiana del Farmaco (AIFA) has been 
obtained on 1 March 2016 with protocol number AIFA/
RSC/P/20735. Patient enrolment will start in December 
2016.
The protocol has been design adhering to the Standard 
Protocol Items: Recommendations for Interventional 
Trials.
Figure 1 shows the flow-chart of the study
Patients diagnosed with probable laboratory supported 
or definite sporadic or familiar ALS according to the 
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revised El Escorial criteria35 will be assessed for eligibility 
(table 1).
sAMPlE sIzE CAlCulAtIon
The sample size has been estimated as the proportion 
of patients progressing to higher stages of disease in 6 
months as measured by the ALS Milano-Torino Staging 
(ALS-MITOS) system36 in our cohort of 200 patients 
with ALS  on riluzole randomised in the Erythropoietin 
in amyotrophic lateral sclerosis (EPOS): a multicentre, 
randomised, double blind, placebo controlled, phase 
III study and followed by the Consortium for 1 year.37 38 
The ALS-MITOS is based on the loss of independent 
functions in the four key domains included in the 
ALSFRS-R (eg, walking/self-care, swallowing, commu-
nicating and breathing). This outcome can overtake the 
intrinsic limitations of the ALSFRS-R scale that is not 
unidimensional and has been proven not to meet the 
modern clinimetrics needs for a single scoring system 
in ALS.39 At baseline, 153 of 200 patients (76.5%) were 
Figure 1 Flow-chart of the Protocolised Management In Sepsis study. ALT, Alanine transaminase; AST, Aspartate 
transaminase;  BMI, body mass index; GGT, Gamma-glutamyl transpeptidase; SAE, serious adverse event; sVC, slow vital 
capacity.
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in stage 0, 44 (22%) were in stage 1, 3 (1.5%) were in 
stage 2 and none was in stage 4. At 6 months follow-up, 
46.6% of patients progressed to a higher stage of 
disease. The ALS-MITOS system was found to predict 
at 6 months, irrespective of the number of functions 
lost, an event included in the primary outcome at 12 
months with a probability of 82% and to correctly iden-
tify a patient who will not have an event included in the 
primary outcome with a probability of 63%.38
Based on these findings, we calculated the sample 
size. The null hypothesis is that guanabenz reduces the 
proportion of patients progressing to a higher stage of the 
disease at 6 months by at least 35% compared with their 
baseline stage and to the placebo group. The alternative 
hypothesis is that guanabenz reduces the proportion of 
patients progressed to a higher stages of the disease by 
less than 35% compared with their baseline stage and to 
the placebo group. If the null hypothesis were rejected, 
it would indicate that guanabenz is not sufficiently prom-
ising to change the progression of ALS in a phase III 
RCT, and in that sense is futile. The study was designed 
to reject the null hypothesis with an alpha of 0.1 and a 
power of 0.85. For this purpose, a sample of 208 patients 
randomised in four treatment arms with allocation 1:1:1:1 
(guanabenz 16 mg + riluzole 100 mg; guanabenz 32 mg 
+ riluzole 100 mg; guanabenz 64 mg + riluzole 100 mg; 
placebo + riluzole 100 mg) is needed.
randomisation
The randomisation unit is at the coordinating centre. 
Eligible patients will be randomised in blocks and strati-
fied by centre with 1:1:1:1 allocation in the four treatment 
arms. Patients will be allocated in one the following treat-
ment arms:
1. guanabenz 16 mg + riluzole 100 mg
2. guanabenz 32 mg + riluzole 100 mg
3. guanabenz 64 mg + riluzole 100 mg
4. placebo + riluzole 100 mg daily.
The expected randomisation period will be of 12 
months or until the achievement of the estimated number 
of patients. The randomisation unit will give the randomi-
sation list exclusively to Cosmo Pharmaceuticals (Lainate, 
Milano, Italy; www. cosmopharma. com) responsible for 
the preparation of investigational drug and placebo. 
The investigational drug/placebo will be dispensed to 
the pharmacy of each participating centre according 
to the randomisation allocation sequence. Treatment 
packs will be supplied for the entire study period along 
with information on how to administer the treatment. 
The randomisation unit will hold the treatment codes of 
each patients and will be available 24 hours a day over the 
entire study period to advise in an emergency whether a 
patient is receiving active or placebo.
Experimental drug preparation
The coordinating centre has purchased the active powder 
(guanabenz) by Medichem SA, Spain. Cosmo Pharma-
ceuticals (Lainate, Milano, Italy; www. cosmopharma. 
com) has prepared the active formulation at the different 
dosages (16 mg, 32 mg, 64 mg) and the placebo. The 
active powder and the investigational drug have been 
produced complying the Good Manufacturing Practices 
of the European Union for active pharmaceutical ingre-
dients and ICH Q7A guidelines. Verum and placebo are 
identical and unrecognisable tablets by form size, weight 
and colour and will be indistinguishable to patients and 
neurologists. Tablets will be prepared in titration kits and 
boxes for the 6-month treatment.
treatment and blindness
All patients will be treated for 6 months since the achieve-
ment of the dose at which they have been randomised 
(16 mg, 32 mg or 64 mg). Active treatment will be started 
at the dose of 8 mg daily and titrated up every 3 days 
to 16 mg, 32 mg or 64 mg in 21 days. All patients will 
take the same number of tablets. Participating centres 
will receive the investigational drug packages for the 
entire study duration within 2 weeks after each patient 
randomisation. Treatment will be taken two times daily 
(morning and evening) for a period of 6 months. All 
patients will be required to take riluzole 100 mg daily; 
patients will be eligible if at this stable dose for at least 
30 days. Not to take riluzole for any reason will not be an 
exclusion criterion. Patients on riluzole at the randomi-
sation will be asked to remain at the stable dose for the 
entire study period. Patients not on riluzole at rando-
misation will not be given riluzole for the entire study 
period.
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
1. Diagnosis of probable, probable laboratory supported or 
definite sporadic or familiar ALS according to the revised El 
Escorial criteria
2. Age >18 years
3. Onset ≤18 months before randomization
4. sVC ≥70% in spinal onset
5. Riluzole 100 mg/day or no riluzole
6. Written informed consent
1. PEG, NIV or tracheotomy
2. Known heart, renal or liver failure
3. Known intolerance to alpha II agonists
4. Known conditions at risk for cardiovascular disorders or 
symptomatic hypotension
5. Participation in a clinical trial within 3 months prior to the 
screening
6. Cognitive impairment
ALS, amyotrophic lateral sclerosis; NIV, non-invasive ventilation; PEG, percutaneous endoscopic gastrostomy; sVC, slow vital capacity.
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PrIMAry outCoME
Proportion of patients progressed to higher stages of 
disease at 6 months (measured by the ALS-MITOS 
system) by at least 35% in the guanabenz arm compared 
with their baseline stage and to the placebo arm (null 
hypothesis in the futility design).
sECondAry outCoMEs
1. Proportion of withdrawals due to adverse events<20%;
2. Decrease in mean decline of ALSFRS-R at 6 months 
in the guanabenz arms compared with placebo arm;
3. Difference in at least one serum biomarker of 
neurodegeneration (creatinine and/or albumin) 
comparing baseline and study end between guanabenz 
and placebo arm.
CoTreaTmenTs
Nutritional status and ventilation can affect survival and, 
therefore, the outcomes. We will strive to a homogeneous 
approach in all the participating centres.
nutrition
The ultimate decision for a feeding tube placement will 
remain a very personal decision of each patient. However, 
malnutrition can affect survival. Therefore, percutaneous 
endoscopic gastrostomy (PEG) or equivalent device (eg, 
radiologically inserted device) will be discussed and 
proposed to all patients in the case of any of the following:
 ► Score 1 or 2 at item 3 of the ALSFRS-R;
 ► Unintentional loss of body weight >10% in the last 3 
months;
 ► Choking during ingestion of food, fluid or medica-
tion.
non-invasive ventilation
Respiratory status declines in patients with ALS  and 
non-invasive ventilation can improve survival. Symptoms 
suggestive of nocturnal hypoventilation (frequent 
arousals, morning headaches, excessive daytime sleep-
iness, vivid dreams) will be recorded in all patients. 
Non-invasive ventilation will be discussed and proposed 
to all patients in the case of any of the following:
 ► dyspnoea (score 0 or 1 at item 10 of the ALSFRS-R)
 ► orthopnoea (score 0 or 1 at item 11 of the ALSFRS-R)
 ► slow vital capacity <50%
 ► abnormal nocturnal oximetry (SaO2 <90% for 4% of 
the overnight recorded time).
safeTy assessmenT
Safety and tolerability of treatment will be controlled at 
every visit. Since the guanabenz is a hypotensive drug, 
blood pressure and side effect of overdose (severe 
dizziness, irritability nervousness, pinpoint pupils, low 
heartbeat, unusual tiredness or weakness) will be moni-
tored40 also through a questionnaire for side effects of 
guanabenz that will be given to each patient.
All patients will be provided a blood pressure diary to 
report measurements taken at home at least once a week 
and the information on when and how to measure the 
blood pressure and the interpretation of the results. 
Patients with symptomatic hypotension (eg, <90/60) 
interfering with daily activities and/or prelipotimic 
events and/or lipotimic events will be withdrawn. The 
Hamilton rating scale for depression41 will be performed 
in all patients at the enrolment visit and at monthly visit. 
Table 2 describes the safety assessment.
data recording and study monitoring
All data will be recorded by an electronic case report 
form (eCRF). The study will be monitored by a certified 
contract research organisation (CRO).
statistical analysis
Statistical analyses will be performed at the Neuroepide-
miology Unit of the coordinating centre.
Table 2 Safety tools that will be used throughout the study period
Screening 
visit
Study-end 
visit
Drop-out 
visit Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6
Blood pressure 
recording
X X X X X X X X X
ECG X X X
Haematological 
exams (liver and 
renal function)
X X X X X X
Medical history X X X
Signs and 
symptoms of 
overdose
X
(Weekly during 
the titration 
period—21 day by 
telephone)
X X X X X
Hamilton scale X X X X X X X
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Primary analysis of efficacy will be performed by 
intention to treat. Per-protocol analysis will be carried 
out after excluding non-compliers (patients who will 
take <80% therapy). Statistics will be tabulated by treat-
ment arm and time. Data will be analysed using t-test, 
Wilcoxon rank-sum test, χ2 test, Fisher's exact test or 
Kaplan-Meier estimator as appropriate. Statistical anal-
yses will be carried out using SAS V.9.3 software (Stata 
Corporation). Randomisation and statistical analysis will 
be performed by different persons.
role of funding
This is an academic, independent clinical research 
project funded by AriSLA. The pharma company from 
which guanabenz is purchased and the company that has 
prepared the investigation drug will not be involved at 
any level in the study. Participating units and patients will 
not be paid.
rolE of PArtICIPAtIng CEntrEs: ProMIsE study grouP
ALS is a rare disease and RCT striving to obtain reliable 
data on the efficacy of candidate neuroprotective molecules 
should be performed with a multicentre design. Our consor-
tium includes 25 ALS centres in Italy and satisfies the criteria 
of complementarily and synergy needed for a RCT in ALS. 
The coordinating centre is experienced in leading RCTs 
and the participating centres have a long-standing collabo-
ration in the field of ALS, both in the clinical management 
of patients and clinical research. It will guarantee a stan-
dardised approach to the diagnosis and management of the 
patients. All partners have participated in a recent phase III 
RCT led by the coordinating centre of the present RCT, and 
can guarantee efficient recruitment and low drop-out rates. 
Participating centres are not involved in other competitive 
trials. All centres are already provided of all the equipment 
needed to assess the patients during the RCT and have 
laboratory units available to store and ship the biological 
samples for biomarkers assays by means of consolidated 
protocols. The analysis of blood and CSF biomarkers will 
be centralised at the coordinating centre. Randomisation 
and statistics centres will be also centralised to orchestrate 
the different phases of the project. All trial activities will be 
monitored by a CRO.
Each centre is expected:
1. To randomise at least eight patients fulfilling including 
and excluding criteria in a period of 12 months and to 
administer the treatment for 6 months;
2. To provide one principal investigator and one 
neurologist to evaluate including and excluding 
criteria, administer treatment and assess primary and 
secondary outcome;
3. To formally adhere to the practice parameters of the 
American Academy of Neurology concerning the 
standardisation of the management of the patient 
in terms of ventilatory support and nutrition. Box 
reports the list of the participating centres.
AdvErsE EvEnts
All adverse events occurring between the first study-related 
procedure and the last study-related procedure will be 
reported. Those meeting the definition of serious adverse 
events (SAE) will be reported using the SAE Form. The 
coordinating centre will evaluate any safety information 
that is spontaneously reported by an investigator beyond 
the time frame specified in the protocol. All adverse 
events, regardless of seriousness, severity or presumed rela-
tionship to study therapy, will be recorded using medical 
terminology in the eCRF. Whenever possible, diagnoses 
should be given when signs and symptoms are due to a 
common aetiology (eg, cough, runny nose, sneezing, sore 
throat and head congestion should be reported as ‘upper 
respiratory infection’). Investigators must record in the 
eCRF their opinion concerning the relationship of the 
adverse event to study therapy. All measures required for 
adverse event management must be recorded in the source 
document and reported according to sponsor instructions. 
The IRCCS Fondazione Istituto Neurologico ‘Carlo Besta’ 
assumes responsibility for appropriate reporting of adverse 
events to the regulatory authorities and reports to the 
investigators all SAE unlisted and associated with the use of 
the drug. The investigator (or coordinating centre where 
box list of the amyotrophic lateral sclerosis (Als) 
centres, locoregional subinvestigators and Italian towns 
participating in the study. thirteen Italian regions will be 
represented and at least one Als centre per regions will 
be involved, providing a large coverage of the national 
territory.
1. IRCCS ‘Carlo Besta’ Neurological Institute (Coordinating Centre)
2. ALS Centre, University of Torino
3. ALS Centre, University of Genova
4. ALS Centre, S. Raffaele Hospital, Milano
5. ALS Centre, ‘S. Maugeri’ Foundation, Milano
6. NEMO Clinical Centre, Milano
7. ALS Centre, IRCCS Istituto Auxologico Italiano, Milano
8. ALS Centre, University of Modena
9. ALS Centre, University of Siena
10. Neurology Unit, University of Ferrara
11. Neurology Unit, Hospital of Udine
12. NESMOS Department, Neuromuscular Disease Unit, Sant'Andrea 
Hospital and University of Rome ‘Sapienza’, Rome
13. ALS Centre, Cagliari
14. ALS Centre, ‘S. Maugeri’ Foundation, Mistretta (ME)
15. ALS Centre, second University of Napoli
16. ALS Centre, University of Padova
17. ALS Centre, University of Novara
18. Neurology Unit, Department of Neuro-Motor Diseases, IRCCS 
Arcispedale Santa Maria Nuova, Reggio Emilia
19. Department of Neurology, University of Pisa
20. ALS Centre, University of Palermo
21. Department of Neurology, University of Chieti
22. ALS Centre, Dpt of Neurology, University of Bari
23. NEMO SUD Clinical Centre, Messina
24. Casa di Cura Privata del Policlinico, ALS Centre, Milano
25. Neurology Unit, Spedali Civili, Brescia
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required) report these events to the appropriate Ethics 
Committee that approved the protocol unless otherwise 
required and documented by the Ethics Committee. In 
compliance with the Italian Health Ministry ‘Decreto 17 
dicembre 2004’, the coordinating centre will provide in 
due time the pharmaceutical company entitled to sell the 
study product in Italy all information on observed serious 
adverse event, if any.
EthICs And dIssEMInAtIon
The study protocol was approved by the Ethics Committee 
of IRCCS ‘Carlo Besta Foundation’ and ALS-Consortium 
(Eudract no. 2014-005367-32) based on the Helsinki 
declaration. All subjects must sign and personally date an 
approved informed consent form after receiving detailed 
written and verbal information about the reason, the 
nature, the required procedures, the intended duration 
and the possible risks and benefits and any discomfort 
associated with the study. He/She should be informed 
that the subject’s participation in the study is voluntary 
and that he/she may refuse to participate or withdraw 
from the trial, at any time, without penalty or loss of 
benefits to which the subject is otherwise entitled. The 
language used in the oral and written information about 
the trial, including the written informed consent form, 
should be as non-technical as practical and should be 
understandable to the subject or the subject’s legally 
acceptable representative and the impartial witness, 
where applicable. The subject must be given ample time 
to read and to understand the patient information sheet 
and opportunity to inquire and ask any clarification 
about the trial before signing the informed consent form. 
Prior to a subject’s participation in the trial, the written 
informed consent form should be signed and personally 
dated by the subject or by the subject’s legally acceptable 
representative, and by the physician who conducted the 
informed consent discussion. When applicable, the inves-
tigator may conduct the informed consent discussion in 
presence of an impartial witness, who should sign and 
personally date the informed consent form. No study 
procedure can be performed before the written informed 
consent has been provided. The informed consent proce-
dure must be done according to the guidelines provided 
in the Declaration of Helsinki and the ICH E6 Guideline 
for Good Clinical Practice.
The subject must be made aware and agree that 
personal information may be scrutinised during audit by 
competent authorities and properly authorised persons. 
However, personal information will be treated as strictly 
confidential and will not be publicly available. By signing 
the investigator statement the investigator assures the 
sponsor that informed consent will be obtained.
Any study subject may be withdrawn from the study at 
any time either at the discretion of the investigator or 
at the request of the study subject. However, the study 
subject is not under any obligation to provide a reason 
for withdrawal.
The trial has been designed following the guideline on 
clinical investigation of medicinal products for the treat-
ment of ALS provided by the European Medicines Agency 
and adopted by the Agenzia Italiana del Farmaco (http://
www. ema. europa. eu/ docs/ en_ GB/ document_ library/ 
Scientific_ guideline/ 2013/ 07/ WC500147005. pdf).
The protocol has been discussed and revised according 
to the suggestions of the Advisory Board
Results will be first presented and discussed with the 
participating centres, the scientific board of AriSLA 
and the Advisory Board. The results of the study will be 
presented at scientific symposia and published in scien-
tific journals only after review and written approval by 
the involved parties in full respect of the privacy of the 
participating subjects. None of the investigators at the 
participating centres can make use of any information 
or data before, during and after the study without the 
written approval from the principal investigator.
rElEvAnCE to PrACtICE/ConClusIon
Neuroprotective treatments able to slow and, hopefully, 
halt the progression of ALS are urgently needed. The 
objective of clinical researchers is to formulate RCTs on 
solid preclinical studies, with strong statistical design, 
feasible in terms of time and economic resources and with 
the ability to obtain results in the shortest time frame. 
It would improve our knowledge on the disease and 
generate hope in patients with ALS enhancing the thera-
peutic alliance and the service done to the community. We 
would like the Protocolised Management In Sepsis trial to 
be a promise in achieving these objectives.
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